ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
New onset steroid-responsive Hashimoto's encephalopathy in the older population: a scoping review.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Visual Hallucinations and Cognitive Impairment as the Initial Presentation of Severe Hypothyroidism in an Elderly Patient: A Case Report.Geriatrics (Basel, Switzerland) · 2026Article
- Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis: A Case Fulfilling Definite Graus Criteria.Journal of community hospital internal medicine perspectives · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHashimoto's encephalopathy (HE) is a rare autoimmune disorder which can mimic late-life neuropsychiatric symptoms as part of a dementia syndrome. Our objective was to review the clinical profile and management outcomes of new onset HE in older adults based on available literature.
methodsWe conducted a comprehensive search for studies on patients aged 65 years and older with newly diagnosed HE across multiple databases, including Medline, Web of Science, Wiley Online Library, and The Cochrane Library, covering publications up to January 2024. Clinical information was extracted and analyzed using Descriptive statistics.
resultsOut of 608 articles screened, 45 articles detailing 51 patients were included. Majority of older patients (n = 48, 94.1%) were initially treated with steroids. Methylprednisolone 1 g/day was given in 37.2% (n = 19) for a minimum of 3 days before tapering. Some initiated a reduced dose of 500 mg/ day (n = 5, 9.8%) with similar outcomes. Response is favorable, with 56.8% (n = 29) returning to near baseline functional status, while 29.4% (n = 15) showed partial improvement.
conclusionEvidence from 51 cases highlight the disorder's variable course in the older population; often mimicking other age-related conditions leading to diagnostic challenges and delays in management. A tailored approach is required, balancing the benefits of immunomodulatory therapies with potential risks. Further research is essential to understand the mechanism of HE in the older population and enhance patient outcomes by developing standardized treatment protocols tailored to this vulnerable population.
Indexed as
Identifiers
40323355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.